ABSTRACT
Purpose To investigate the expression of CYP4 A11 and CYP4 A22 in triple-negative breast carcinoma (TNBC) and its relationship with clinicopathological features and M2 tumor-associated macrophages (TAMs). Methods 72 cases of TNBC with clinical and pathological data were collected. The expression of CYP4 A11 and CYP4 A22 in the carcinoma cells and the expression of CD68 and CD163 of the TAMs were detected by immunohistochemically and analyzed with image processing software. The relationship between the expressions of CYP4 A11 and CYP4 A22 with clinicopathologic features and its correlation of the M2 state of TAMs was studied. Results Both the immunohistochemically staining scores of CYP4 A11 and CYP4 A22 were higher in cancer tissues than that in breast tissues (P<0.001, P<0.001). The higher expression of CYP4 A11 was associated with tumor diameter increase (P<0.001), lymph node metastasis (P<0.001), higher clinical stage (P<0.001) and higher Ki-67 index (P=0.011). Both the positive rates of CD68 and CD163 in the high expression group of CYP4 A11 were higher than those in the low expression group of CYP4 A11 (P=0.021, P<0.001). The higher expression of CYP4 A22 was associated with lymph node metastasis (P<0.001), higher clinical stage (P=0.006), higher recurrence rate (P<0.001), and higher Ki-67 index (P=0.040).The positive rates of CD163 in the high expression group of CYP4 A22 was higher than that in the low expression group of CYP4 A22 (P<0.001). Conclusion Both the expression of CYP4 A11 and CYP4 A22 may be associated with M2 polarization state of TAMs, high proliferative activity and lymph node metastasis in the TNBC.
ABSTRACT
Aim To investigate the protective effect of bezafibrate on renal injury and the changcs of 20- HETE in mice with diabetic nephropathy. Methods A diabctic model was established by long-term high-energy feeding combined with streptozotocin. The structural and functional changes of kidney were evaluated by renal pathological examination and blood urea nitrogen (BUN), serum creatinine ( Scr) , urinary albumin levels. The expressions of PPAIls and CYP4A protein were detected by Western blot. The level of 20-HETE was measured by ELISA kit. Results After four weeks with high-energy feeding, streptozotocin (40 mg • kg-1 • d"1 i. p) administration had been performed for five days. Then after seven days,fasting blood glucose (FBG) of mice exceeded 11.1 nimol • L"1, which suggested the establishment of the diabetic model. After four weeks of diabetic onset, the levels of BUN,Scr,urinary albumin increased significantly (P er and thickened basement membrane were observed in diabetic mice. Meanwhile,the expressions of PPARs and CYP4A protein in the kidney and the content of 20-HETE in serum decreased in model group (P <0. 01). With bezafibrate supplementation (75 mg • kg"' • d"1) for four weeks, both the structure and function of kidney were improved in diabetic mice,with the up-regulation of PPARs and CYP4A protein expressions and the increase of 20-HETE level (P <0. 01 ). Conclusions Bezafibrate can ameliorate renal injury in diabetic mice, which may be related to activating CYP4A-20-HETE.
ABSTRACT
Aim: To investigate the ameliorative effects of naringenin on renal injury and its roles in 20-HETE in diabetic mice. Methods: A diabetic model was established by long-term high-energy feeding combined with streptozotocin. The structural and functional changes of kidney were evaluated by renal pathological examination and blood urea nitrogen(BUN), serum creatinine(SCr), urinary albumin levels. The expression of CYP4A protein was detected by Western blot. The level of 20-HETE was measured by ELISA kit. Results: After four weeks of high-energy feeding, streptozotocin (40 mg. kg-1. d-1, IP) was given for five days. Then after seven days, fasting blood glucose of mice exceeded 11.1 mmol L-1, which suggested the establishment of diabetic model. After four weeks of diabetic onset, the levels of BUN, SCr, urinary albumin increased significantly(P <0. 01); kidney index(renal weight/body weight) and glomerular volume were raised(P <0. 01); increased collagen fiber and thickened basement membrane were observed in diabetic mice. Meanwhile, the expression of CYP4A protein in the kidney and the content of 20-HETE in serum decreased in model group (P < 0. 01). With naringenin supplementation(25 or 75 mg · kg-1 · d-1) for four weeks, both the structure and function of kidney were improved in diabetic mice, with the up-regulation of CYP4A protein expression and the increase of 20- HETE level(P < 0. 05). Conclusion: Naringenin can ameliorate renal injury in diabetic mice, which may be related to activating CYP4A and increasing 20-HETE.
ABSTRACT
In this study, the effects of honokiol (HN) treatment for 24 h on lipid synthesis was examined in HepG2 cells. The parameters include intracellular lipid droplet and the expression of SREBP-1c and PNPLA3, glucose uptake, and oxidative stress including the expression of CYP2E1 and CYP4A in normal, TO901317 (TO)- and oleic acid (OA)-treated HepG2 cells. The lipid droplets were detected by oil red O staining. The glucose uptake was measured by fluorescence spectrophotometry using[2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino)-2-deoxyglucose, 2-NBDG] as probe. The expression levels of target genes were detected by quantitative PCR and Western blot. The results showed that:① TO (5 μmol·L−1) and OA (0.5 mmol·L−1) treatment increased the levels of intracellular lipid accumulation and the mRNA and protein expression of SREBP-1c and PNPLA3. After HN (10, 20, 40 μmol·L−1) treatment for 24 h, the lipid accumulation and the expression of SREBP-1c and PNPLA3 were all decreased in the tested cells. ② OA treatment significantly suppressed glucose uptake, while HN treatment dose-dependently increased the glucose uptake in OA-treated cells. ③ Compared with control group, CYP2E1 protein level significantly decreased in the three tested cells, and CYP4A protein level significantly decreased only in OA-treated cells following HN treatment. The above results suggest that HN may attenuate lipid accumulation by suppressing the expression of SREBP-1c and PNPLA3, and reduce lipid peroxidation and insulin resistance by down-regulation of the protein levels of CYP2E1 and CYP4A in HepG2 cells with steatosis.
ABSTRACT
Objective To investigate the association between single nucleotide polymorphisms (SNPs) in CYP4A11 and ApoB、 ApoE genesandthe risk of essential hypertension. Methods By means of correlation analysis, this case-controlled study included a total of 350 essential hypertension patients admitted in the first Hospital of Xi'an from June 2012 to December 2016, and another 350 cases with matched ages and sexes enrolled for routine check-ups as the healthy control group. The genotypes of CYP4A11 and ApoB、 ApoE genes were determined by MassARRAY method. SPSS 21.0 software was used to determine the correlation between SNPs and the risk of primary hypertension.Results Comparing the allele frequencies of SNPs, we found rs1126742 (OR=1. 45, 95 % CI, 1.09-1.92,P=0.008)、 rs3890011 (OR=1.98, 95 % CI, 1.06-1.85, P=0.001) and rs9332978 (OR=1.54, 95%CI, 1.27-1.91,P=0.004) on CYP4A11 were significantly associated with an increased risk of essential hypertension; XbaⅠpolymorphism in ApoB gene was associated with essential hypertension risks (OR=1.55,95%CI, 1.15-2.55,P=0.001);ε4 in ApoE gene was also found associated with essential hypertension risks (OR=1.49, 95 % CI, 1.09-2.35, P=0.012), while ε2 andε3 not associated.Comparing the genotype frequencies of SNPs,we found the GG genotype of rs9332978, TC and CC genotype of rs1126742, CG and GG genotypes of rs3890011 were associated with increased risks of essential hypertension (P＜0.05) .The X -X- genotype of XbaⅠin ApoB gene were associated with increased risks of essential hypertension (OR=2.45, 95%CI, 1.25-3.25, P=0.035) . The E2/E4、E3/E4、E4/E4 genotype of ApoE were associated with increased risks of essential hypertension (P＜0.05).In the genetic model analysis, we found that the minor allele "A" of rs9332978 was associated with an increased risk of essential hypertension under dominant model (P＜0.05) . The minor allele "T" of rs1126742 was associated with increased risks essential hypertension under dominant and recessive models (P＜0.05) . Conclusion Gene polymorphisms of CYP4A11、ApoB and ApoE play an important role in the occurrence and development of essential hypertension.
ABSTRACT
Cytochrome P450 4A11 (CYP4A11) is a fatty acid hydroxylase enzyme expressed in human liver. It catalyzes not only the hydroxylation of saturated and unsaturated fatty acids, but the conversion of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE), a regulator of blood pressure. In this study, we performed a directed evolution analysis of CYP4A11 using the luminogenic assay system. A random mutant library of CYP4A11, in which mutations were made throughout the entire coding region, was screened with luciferase activity to detect the demethylation of luciferin-4A (2-[6-methoxyquinolin-2-yl]-4,5-dihydrothiazole-4-carboxylic acid) of CYP4A11 mutants in Escherichia coli. Consecutive rounds of random mutagenesis and screening yielded three improved CYP4A11 mutants, CP2600 (A24T/T263A), CP2601 (T263A), and CP2616 (A24T/T263A/V430E) with ~3-fold increase in whole cells and >10-fold increase in purified proteins on the luminescence assay. However, the steady state kinetic analysis for lauric acid hydroxylation showed the significant reductions in enzymatic activities in all three mutants. A mutant, CP2600, showed a 51% decrease in catalytic efficiency (k cat/K m) for lauric acid hydroxylation mainly due to an increase in K m. CP2601 and CP2616 showed much greater reductions (>75%) in the catalytic efficiency due to both a decrease in k cat and an increase in K m. These decreased catalytic activities of CP2601 and CP2616 can be partially attributed to the changes in substrate affinities. These results suggest that the enzymatic activities of CYP4A11 mutants selected from directed evolution using a luminogenic P450 substrate may not demonstrate a direct correlation with the hydroxylation activities of lauric acid.